TOPIC 319 PHASE I; TECHNOLOGY TO GENERATE ANTI PEPTICE CAPTURE REAGENS AFFINITY E

本SBIR合同规定的第一阶段活动和预期交付内容包括：1)开发 概念验证技术，可靠地产生抗肽捕获试剂，可以 2)证明所研制的捕捉剂具有良好的重复性。 免疫沉淀目标多肽；3)与CPTC社区、私营和公共部门合作，以 确定用于验证检测的最低表征标准；4)至少产生亲和试剂 10个蛋白型多肽，表现出高亲和力、特异性和免疫沉淀性能；5) 为NCI提供足够的试剂，以对10个独立的多肽中的每一个进行10次测试 评估；6)向NCI CPTC评估小组提交调查结果，展示捕获试剂如何 提高了生产中的成本效益和生产能力。

The stated Phase I activities and expected deliverables of this SBIR Contract include: 1) Development of proof-of-concept technologies that reliably generate anti-peptide capture reagents that can immunoprecipitate the target peptides; 2) Demonstrate that the capture reagents developed can reproducibly immunoprecipitate the target peptides; 3) Work with the CPTC community, private and public sector to identify minimum characterization criteria for validation of the assays; 4) Generate affinity reagents to at least ten proteotypic peptides and demonstrate high affinity, specificity and immunoprecipitation performance; 5) Make available to NCI sufficient reagents to perform 10 test runs for each of the ten peptides for independent evaluation; 6) Present findings to an NCI CPTC Evaluation Panel demonstrating how the capture reagents have improved cost effectiveness and throughput capabilities in production.